J. Goldman & Co LP Takes $5.02 Million Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

J. Goldman & Co LP acquired a new stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) during the 4th quarter, HoldingsChannel.com reports. The institutional investor acquired 296,045 shares of the biotechnology company’s stock, valued at approximately $5,024,000.

Other large investors also recently modified their holdings of the company. Virtus ETF Advisers LLC raised its position in Arcturus Therapeutics by 38.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 1,132 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in Arcturus Therapeutics in the 4th quarter worth approximately $71,000. National Bank of Canada FI raised its position in Arcturus Therapeutics by 639.6% in the 4th quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company’s stock worth $94,000 after purchasing an additional 4,784 shares during the last quarter. Kennedy Capital Management LLC raised its position in Arcturus Therapeutics by 22.7% in the 4th quarter. Kennedy Capital Management LLC now owns 10,987 shares of the biotechnology company’s stock worth $186,000 after purchasing an additional 2,036 shares during the last quarter. Finally, SG Americas Securities LLC raised its position in Arcturus Therapeutics by 45.0% in the 4th quarter. SG Americas Securities LLC now owns 11,940 shares of the biotechnology company’s stock worth $203,000 after purchasing an additional 3,705 shares during the last quarter. 94.54% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently weighed in on ARCT. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of Arcturus Therapeutics in a research report on Thursday, April 10th. Wells Fargo & Company dropped their target price on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, March 7th. Canaccord Genuity Group dropped their target price on shares of Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating for the company in a research report on Monday, March 10th. Finally, BTIG Research set a $48.00 target price on shares of Arcturus Therapeutics and gave the company a “buy” rating in a research report on Monday, March 10th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $59.20.

Arcturus Therapeutics Stock Performance

Shares of NASDAQ:ARCT opened at $10.98 on Monday. Arcturus Therapeutics Holdings Inc. has a 52-week low of $8.04 and a 52-week high of $45.00. The company has a market capitalization of $297.79 million, a P/E ratio of -4.95 and a beta of 2.36. The company has a 50-day simple moving average of $11.87 and a 200 day simple moving average of $15.43.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.78). The company had revenue of $22.77 million during the quarter, compared to the consensus estimate of $44.64 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. As a group, equities analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.22 earnings per share for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.